Abiopharma

🔍 Stuart Cormac (Executive)

Company: AerCap Holdings N.V. (AER)

Report Date: 2026-03-24

Detailed Transactions and Holdings:

• Acquired 109 shares of Ordinary Shares at $135.21 per share (Direct)
  Date: 2026-03-24 | Code: J | equity_swap_involved: 0 | shares_owned_after: 403.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-03-24 | Code: H | shares_owned_after: 270.00 | Footnotes: F3
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-03-24 | Code: H | nature_of_ownership: By AerCap Equity Incentive Plans Trust | shares_owned_after: 24,613.00 | Footnotes: F4

Footnotes:

• F1: Represents the compensation, on a per share basis, forgone by the reporting person to receive the allocation of shares reported herein.
• F2: Represents Ordinary Shares awarded pursuant to equity-based awards that are held in a trust for three years in order to achieve certain tax benefits under Irish law, after which the shares will either be released to the reporting person or sold and the proceeds released to the reporting person.
• F3: Includes shares previously held in the AerCap Approved Profit Sharing Scheme Trust that were distributed to the reporting person.
• F4: Represents Ordinary Shares granted as compensatory awards and held in a trust in order to achieve certain tax benefits under Irish law, after which the shares (to the extent vested) will be released to the reporting person. Of these awards, 15,787 are restricted shares that remain subject to service-based vesting conditions and 8,826 are restricted shares that remain subject to service- and performance-based vesting conditions.